Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Executive Summary
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure